 |
10 Diseases |  |
0 Trials |
|
0 Trials |  |
10 News |  |
- | Atu027 / Silence Therap
Journal: An aerotaxis receptor influences invasion of Agrobacterium tumefaciens into its host. (Pubmed Central) - Feb 13, 2024
Furthermore, deleting Atu1027 impaired the biofilm formation and pathogenicity of A. tumefaciens. Collectively, our findings demonstrated that Atu1027 functions as an aerotaxis receptor that affects agrobacterial chemotaxis and the invasion of A. tumefaciens into its host.
- || gemcitabine / Generic mfg.
Clinical, P1/2 data, Journal: Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib/IIa Study. (Pubmed Central) - Nov 1, 2020
P1/2
In pts with metastatic APC, twice-weekly Atu027 is associated with significantly improved outcomes. Our clinical results support the significant involvement of the vascular endothelium in the spread of cancer, and thus the further investigation of its target role.
- | Atu027 / Silence Therap
Trial completion, Combination therapy, Metastases: Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) (clinicaltrials.gov) - Mar 11, 2016
P1/2, N=29, Completed, Sponsor: Silence Therapeutics GmbH
Our clinical results support the significant involvement of the vascular endothelium in the spread of cancer, and thus the further investigation of its target role. Active, not recruiting --> Completed
- | Atu027 / Silence Therap
Enrollment closed, Combination therapy, Metastases: Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) (clinicaltrials.gov) - Nov 18, 2014
P1/2, N=30, Active, not recruiting, Sponsor: Silence Therapeutics GmbH
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Atu027 / Silence Therap
Enrollment open, Combination therapy, Metastases: Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) (clinicaltrials.gov) - Mar 26, 2013
P1/2, N=30, Recruiting, Sponsor: Silence Therapeutics GmbH
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Atu027 / Silence Therap
New P1/2 trial, Combination therapy, Metastases: Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) (clinicaltrials.gov) - Mar 7, 2013
P1/2, N=30, Recruiting, Sponsor: Silence Therapeutics GmbH
- Atu027 / Silence Therap
Trial completion, Metastases: Study With Atu027 in Patients With Advanced Solid Cancer (clinicaltrials.gov) - Sep 16, 2012
P1, N=34, Completed, Sponsor: Silence Therapeutics AG
Not yet recruiting --> Recruiting Recruiting --> Completed